ReviewBiomolecules2015
Overview of Glutamatergic Dysregulation in Central Pathologies.
Review in Biomolecules, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04785521 (Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery), which is not on this map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Who cites it
67 citing papers in PubMed.
- Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.Advances in therapy · 2018Trial
- Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.Journal of Parkinson's disease · 2017Trial
- Comorbidity Mechanism and Management of Chronic Low Back Pain and Major Depressive Disorder: From Neural Circuit Remodeling to Precision Medicine.Brain and behavior · 2026Review
- Barbaloin Attenuates Cisplatin-Induced Hippocampal Neurotoxicity by Suppressing Oxidative Stress, Neuroinflammation, and Apoptosis: In Vivo and In Silico Evidence.Journal of biochemical and molecular toxicology · 2026Article
- PKMζ in the prefrontal cortex alters cocaine cue-induced reinstatement in a sex-specific manner.Psychopharmacology · 2026Article
- Modulation of Lingo-1 and NMDA receptor expression by memantine and vitamin D3 co-therapy attenuates motor and non-motor symptoms in essential tremor.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Emerging pathological mechanisms of Alzheimer's disease pathogenesis: from neuroimmune interactions to intercellular communication.Frontiers in aging neuroscience · 2026Review
- Review
- Interplay Among Synaptic Glutamate Release and Excitotoxicity: Neuronal Damage and Graphene-Based Materials Related Protection.Life (Basel, Switzerland) · 2025Review
- Drug treatment alters performance in a neural microphysiological system of information processing.Communications biology · 2025Article
- Role of mGluR7 in Alzheimer's disease: pathophysiological insights and therapeutic approaches.Inflammopharmacology · 2025Review
- The endogenous glutamatergic transmitter system promotes collagen synthesis in cardiac fibroblasts under hypoxia.Frontiers in cardiovascular medicine · 2025Article
- Investigation into Antioxidant Mechanism ofFoods (Basel, Switzerland) · 2024Article
- Bone-organ axes: bidirectional crosstalk.Military Medical Research · 2024Review
- Tet controls axon guidance in early brain development through glutamatergic signaling.iScience · 2024Article
- Plasma metabolomic profile in orthostatic intolerance children with high levels of plasma homocysteine.Italian journal of pediatrics · 2024Article
- Toxoplasma-induced behavior changes - is microbial dysbiosis the missing link?Frontiers in cellular and infection microbiology · 2024Review
- Sex differences in glutamate transmission and plasticity in reward related regions.Frontiers in behavioral neuroscience · 2024Review
- Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease.Central nervous system agents in medicinal chemistry · 2024Review
- In vivo magnetic resonance spectroscopy by transverse relaxation encoding with narrowband decoupling.Scientific reports · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As the major excitatory neurotransmitter in the mammalian central nervous system, glutamate plays a key role in many central pathologies, including gliomas, psychiatric, neurodevelopmental, and neurodegenerative disorders. Post-mortem and serological studies have implicated glutamatergic dysregulation in these pathologies, and pharmacological modulation of glutamate receptors and transporters has provided further validation for the involvement of glutamate. Furthermore, efforts from genetic, in vitro, and animal studies are actively elucidating the specific glutamatergic mechanisms that contribute to the aetiology of central pathologies. However, details regarding specific mechanisms remain sparse and progress in effectively modulating glutamate to alleviate symptoms or inhibit disease states has been relatively slow. In this report, we review what is currently known about glutamate signalling in central pathologies. We also discuss glutamate's mediating role in comorbidities, specifically cancer-induced bone pain and depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.